This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 9, 2012 9:00 am ET
Vincent J. Milano – Chairman, President and Chief Executive Officer
J. Peter Wolf – Vice President, General Counsel and Secretary
Charles A Rowland – Vice President, Chief Financial Officer
Colin Broom – Vice President and Chief Scientific Officer
Daniel B. Soland – Vice President and Chief Operating Officer
Brian Abrahams – Wells Fargo Securities
Geoff Meacham – JPMorgan
Thomas Wei – Jefferies & Company
Rachel McMinn – Bank of America Merrill Lynch
Lisa Bayko – JMP Securities
Brian Skorney – Brean Murray
Mario Corso – Caris & Company
Philip Nadeau – Cowen & Company
Stephen Willey – Stifel Nicolaus & Company, Inc.
Joseph Schwartz – Leerink Swann Llc
Good morning everyone, and welcome to the ViroPharma Second Quarter 2012 Results Conference Call. Today’s call is being recorded and is expected to last one hour. At this time, I will now turn the call over to ViroPharma’s Chief Executive Officer, Vin Milano. Please go ahead.
Vincent J. Milano
Thank you, Operator. Good morning, and welcome to everyone joining us on today’s call to discuss our performance for the second quarter of 2012. I’m joined by the other members of the ViroPharma management team, as well as Rich Morris, Will Roberts, and Bob Doody. Before we proceed, Pete Wolf, our General Counsel will provide you of our potential to make forward-looking statements. Pete?
J. Peter Wolf
Thanks, Vin. During this call, we will make forward-looking statements certain statements such as those regarding our expectations for financial results including guidance, peak year, net sales for Cinryze, peak year European net sales and tax rates, manufacturing capacities, the timing of clinical studies, potential or product candidates and clinical development, changes in channel inventory, our commercial launches of Cinryze, Plenadren and Buccolam in Europe and our ability to continue to identify additional Cinryze patients are examples of such forward looking statements.